-+ 0.00%
-+ 0.00%
-+ 0.00%

ARCHIMED to acquire Esperion for $3.16 per share plus milestone CVR

PUBT·05/01/2026 11:02:41
Listen to the news
ARCHIMED to acquire Esperion for $3.16 per share plus milestone CVR
  • Funds managed by ARCHIMED agreed to acquire Esperion in a deal valued at up to USD 1.1 billion on a fully diluted basis.
  • Esperion shareholders will receive USD 3.16 per share in cash at closing.
  • Deal includes a non-tradeable contingent value right tied to up to USD 100 million of aggregate milestone payments linked to future net sales performance.
  • Transaction is expected to close in Q3 2026, subject to shareholder vote and required regulatory clearances.
  • Esperion is expected to become privately held following closing, ending its Nasdaq listing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605010700PRIMZONEFULLFEED9711345) on May 01, 2026, and is solely responsible for the information contained therein.